Key Highlights

  • Edgewise Therapeutics (NASDAQ:EWTX) booked USD 1,166.2 million of third-quarter net income, equal to USD 9.65 a diluted share, with most of it coming from roughly USD 1,348.1 million recorded on the sevasemten divestiture.
  • Dianthus Therapeutics (NASDAQ:DNTH) posted a loss of USD 46.6 million for the quarter, or USD 0.81 a share, while reporting USD 1.2 billion of cash that management expects to last into 2030.
  • Nuvation Bio (NYSE:NUVB) pushed total Revenue up to USD 45.0 million, while the prior year showed USD 13.1 million, with IBTROZI product sales supplying USD 27.5 million of that, and reduced its net loss to USD 41.9 million.
  • Arcus Biosciences (NYSE:RCUS) recorded a USD 128 million loss against USD 9 million of revenue, and an October sale of 16.4 million shares at USD 17.50 brought in roughly USD 288 million gross.

Edgewise Therapeutics (NASDAQ:EWTX): One-Time Sale Gain Turns the Quarter Positive

Edgewise Therapeutics (NASDAQ:EWTX) released its third-quarter numbers on November 4, 2026, with Net Income of USD 1,166.2 million, roughly USD 1.17 billion, which equals USD 9.65 per diluted share. A year earlier the company had lost USD 40.7 million. The swing traces to roughly USD 1,348.1 million booked on the disposal of sevasemten and its muscular dystrophy program to Servier, a transaction that closed July 10, 2026. Upfront cash of USD 1,396.1 million came in, with another USD 153.9 million parked in escrow, while USD 155.3 million of tax expense was recorded against the gain. Stripped of that gain, the operating picture was a USD 46.1 million loss from operations, and management expects significant losses to persist. Cash, cash equivalents and marketable securities stood at USD 1,743.9 million on September 30, 2026, a balance management judges sufficient to fund planned outlays for a minimum of 12 months. Its focus has shifted toward cardiovascular medicine: EDG-7500 for hypertrophic cardiomyopathy is the lead, with a Phase 3 study scheduled to open in the fourth quarter of 2026. Research spending is projected to rise sharply. The filing contains no revenue figures and no share price reaction.

Dianthus Therapeutics (NASDAQ:DNTH): Higher Trial Spending Set Against a 2030 Cash Horizon

For the period ended September 30, 2026, Dianthus Therapeutics (NASDAQ:DNTH) recorded a loss of USD 46.6 million, which equals USD 0.81 a share. The prior-year figures were USD 36.8 million in total and USD 0.97 a share. The clinical-stage developer is advancing claseprubart, a subcutaneous antibody aimed at autoimmune and neuromuscular conditions. Even with a bigger total loss, the per-share figure improved, since the share count expanded. Spending on operations reached USD 59.7 million, up from USD 40.7 million, while interest and Investment Earnings reached USD 12.1 million versus USD 3.7 million before, as cash balances grew. Cash, cash equivalents and investments came to USD 1.2 billion, which the company believes can carry operations into 2030. A September 18, 2026 at-the-market agreement lets the company sell up to USD 500 million of stock over time, a method that releases shares in small amounts and may dilute existing holders. Data from the Phase 2 MoMeNtum study, which now enrolls 46 patients in multifocal motor neuropathy, are slated for December 2026. Management still expects to require additional capital, and a shortfall could delay or end the trials.

Nuvation Bio (NYSE:NUVB): IBTROZI Sales Climb From a Small Base

Nuvation Bio (NYSE:NUVB), a global oncology company established in 2018, put out its quarterly filing on November 4, 2026. Total revenue reached USD 45.0 million, compared with USD 13.1 million a year earlier, and net IBTROZI product revenue came in at USD 27.5 million versus USD 7.7 million. The approved use covers adults with cancer that is locally advanced or has spread, specifically ROS1-positive non-small cell lung cancer, and sales began in the United States in June 2025, which keeps the prior-year base small. On those two published figures, product revenue is about 3.6 times larger, a calculation made for this article. From USD 55.8 million a year earlier, the loss shrank to USD 41.9 million, which is USD 0.12 a share, partly thanks to a sales-based milestone of USD 5.0 million received from Innovent. Over nine months the comparison is flattered by an upfront Eisai payment that added USD 58.7 million to license revenue. The company holds USD 663.4 million in cash and marketable securities, a sum it describes as sufficient for at least 12 months of needs. An accumulated Deficit of USD 1,214.7 million remains, and the company expects it will need substantial funding over time. No numerical outlook, analyst consensus or share price move appears in the document.

Arcus Biosciences (NYSE:RCUS): A USD 288 Million Raise Stretches the Runway to 2029

Focused on cancer and immunology, Arcus Biosciences (NYSE:RCUS) is a late clinical-stage biopharmaceutical company whose Quarterly Report came out November 4, 2026. Revenue landed at USD 9 million, down from USD 26 million, while the loss totaled USD 128 million, which is USD 1.00 a share, compared with USD 135 million, or USD 1.27 a share, a year before. Costs to run the Business dropped from USD 168 million to USD 140 million. At the end of the third quarter, USD 694 million sat in cash, cash equivalents and marketable securities. An underwritten October deal placed 16.4 million shares at USD 17.50 apiece, generating about USD 288 million before costs. Management argues that current cash plus those proceeds will fund planned operations into 2029, yet it concedes more money will still be needed. Without product sales, Arcus saw Gilead's option rights under its 2020 collaboration expire on July 14, 2026. In October the company released casdatifan data in clear cell renal cell carcinoma, with a 50% confirmed response rate across 30 first-line patients; these are early cohort readings, not randomized comparisons. The weighted share count rose from 106.5 million to 127.4 million, a dilution the offering explains.

Where Things Stand

Edgewise's USD 1.17 billion stems from a one-time sale gain, so the profit does not reflect recurring operations, and the company still reported a USD 46.1 million operating loss and no revenue. The other three are losing money the way clinical-stage biotechs normally do. Dianthus Therapeutics (NASDAQ:DNTH) shows a USD 46.6 million loss and signals funding into 2030. Nuvation Bio (NYSE:NUVB) shows a USD 41.9 million loss and cites at least 12 months of cash. Arcus Biosciences (NYSE:RCUS) posted USD 128 million of losses and looks to 2029 after its October financing. Upcoming checkpoints: Edgewise's Phase 3 launch, the MoMeNtum data due in December, IBTROZI sales momentum and casdatifan developments.